Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

Baseline is Day 1 of the study, prior to first dose. CGI-S is a questionnaire completed by the clinician which evaluates the severity of mental illness of a participant at a specific point in time. It consists of 7 categories with the lower categories indicating less illness and the higher numbered categories indicating greater severity of illness: 0=not assessed; 1=normal, not at all ill; 2=borderline mentally ill; 3= mildly ill; 4=moderately ill; 5= markedly ill; 6=severely ill; 7=among the most extremely ill.

Time frame: Baseline to Week 348

Population: Safety Population - all participants who received at least one dose of drug. N=number of participants who were analyzed at each specific time point. Baseline N=97, 20 for first and second arms, respectively.

Mean exposure is mean number of milligrams per day (mg/day) of aripiprazole administered to the participants.

Time frame: Day 1 to Day 1170

Population: N=number of participants receiving drug at Days indicated.

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.

Time frame: Baseline to Week 348

Population: Safety Population: all participants with at least 1 dose of study drug.

Clinically relevant abnormalities: greater than, equal to (\>=); less than, equal to (\<=). Upper limits of normal (ULN). milligram per deciliter (mg/dL); milliequivalent per liter (mEq/L); nanograms per milliliter (ng/mL);outside of normal range inclusive (): alanine transaminase (ALT\>= 3\*ULN; aspartate aminotransferase (AST \>=3\*ULN; alkaline phosphatase \>=3\*ULN; total bilirubin \>= 2.0 mg/dL; blood urea nitrogen \>= 30mg/dL; calcium (8.40 - 9.90 mg/dL); chloride (85.00 - 108.00 mEq/L); total cholesterol (140.0 - 200.0 mg/dL); cholesterol high density (HDL) and low density (LDL) lipoprotein (39.0 - 116.0 mg/dL); creatine kinase (15.0 - 170.0 U/L); creatinine \>=2.0 mg/dL; prolactin (3.00 - 29.00 ng/mL); sodium (136.0 - 144.0 mEq/L); Glucose fasting (70.0 - 110.0 mg/dL); triglycerides (58.0 - 164.0 mg/dL; uric acid male \>= 10.5, female \>= 8.5mg/dL. Baseline is Day 1 of the study, prior to study drug administration.

Time frame: Baseline to end of study (Week 348)

Population: Safety Population: all participants with at least 1 dose of study drug. Number of participant analyzed is given as N in each category of laboratory test.

Potentially clinically relevant abnormality or change relative to baseline: sinus tachycardia: \>= 120 beats per minute (bpm) and increased \>= 15 bpm; sinus bradycardia: \<= 50 bpm and decrease \>= 15 bpm; supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial flutter: not present to present. First degree atrioventricular (A-V) block: PR interval(beginner of P wave to beginning of complex of Q, R, and S waves) \>= 0.20 seconds (sec) and increase \>= 0.05 sec; second and third degree A-V block, right bundle branch block (RBB) block, left bundle branch block (LBB) block: not present to present; other intraventricular block: QRS (complex of Q, R and S waves) \>= 0.12 sec and increase \>= 0.02 sec. Myocardial ischemia not present to present. QT interval with Bazett's correction (QTcB) or Fridericia's correction (QTcF) \>= 450 milliseconds (msec) and elevation of 10% over baseline.

Time frame: Baseline to end of study (Week 348

Population: Safety Population: all participants with at least 1 dose of study drug. Number of participants analyzed is given as N in each ECG parameter and includes those treated participants with ECG measurements.

Clinically relevant laboratory abnormality: Hemoglobin male \<= 11.5 g/dL; female \<= 9.5 g/dL. Hematocrit male \<= 37 and 3 point decrease from baseline (BL); female \<=32 and 3 point decrease from BL. Leukocytes \<= 2800 mm\^3 or \>= 16000 mm\^3; eosinophils \>=10%. Baseline is Day 1 of the study, prior to study drug administration.

Time frame: Baseline to end of study (Week 348)

Population: Safety Population: all participants with at least 1 dose of study drug. Number of participant analyzed is given as N in each category of laboratory test.

Vital signs include standing, sitting and supine systolic and diastolic blood pressure, measured in millimeters of mercury (mmHg) and standing, sitting and supine heart rate, measured in beats per minute. Baseline (BL) is Day 1 of the study, prior to study drug administration. Criteria for identifying vital sign values as clinically relevant: Systolic blood pressure (criterion value=90-180 mmHg) change relative to baseline: increase of greater than, equal to (\>=) 20; decrease of \>= 20 mmHg. Diastolic blood pressure (criterion value=50 - 105 mmHg) change relative to baseline: increase of \>= 15; decrease of \>= 15 mmHg. Heart rate (criterion value=50-120bpm) change relative to baseline: increase \>=15; decreased \>= 15 mmHg. To be clinically significantly abnormal: value must meet the criterion value and also represent a change from the participant's pre-treatment value of at least the magnitude shown in the change relative to baseline.

Time frame: Baseline to end of study (Week 348)

Population: Safety Population: all participants with at least 1 dose of study drug. Number of participants analyzed is given as N in each vital sign parameter and includes those treated participants with vital sign measurements.